SERA PROGNOSTICS, INC. SERA
We are a women's health company utilizing our proprietary proteomics and bioinformatics platform, and significant data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. Our vision is to become the global leader in high-value women's health diagnostics. We plan to do this by taking a holistic approach to providing pivotal and actionable information to pregnant women, their physicians, and health care payers to significantly enhance a mother's pregnancy journey, improve maternal and neonatal health, and reduce health care costs. We believe that our method of combining the disciplines of proteomics and bioinformatics with rigorous clinical testing, data, and economic analysis enables us to provide physicians and expectant mothers with personally insightful, clinically meaningful, and economically impactful information designed to improve the pregnancy experience and outcomes for mothers and babies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $81.0K | $77.0K | $306.0K | $268.0K | $82.0K | $25.0K | — |
| Cost of revenue | $164.0K | $82.0K | $210.0K | — | — | — | — |
| Gross profit | -$83.0K | -$5.0K | $96.0K | — | — | — | — |
| R&D | $13.2M | $14.7M | $15.2M | $14.2M | $11.0M | $7.8M | — |
| SG&A | $16.7M | $16.1M | $16.3M | $16.8M | $14.1M | $6.6M | — |
| Total operating expenses | $36.6M | $36.7M | $40.1M | $45.9M | $35.5M | $18.0M | — |
| Operating income | -$36.5M | -$36.6M | -$39.8M | -$45.7M | -$35.4M | -$18.0M | — |
| Interest expense | $9.0K | $28.0K | $55.0K | — | — | — | — |
| Pre-tax income | -$31.9M | -$32.9M | -$36.2M | -$44.2M | -$35.0M | -$19.8M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$31.9M | -$32.9M | -$36.2M | -$44.2M | -$35.0M | -$19.8M | — |
| EPS, basic | -0.67 | -0.99 | -1.16 | -1.43 | -2.33 | -12.76 | — |
| EPS, diluted | -0.67 | -0.99 | -1.16 | -1.43 | -2.33 | -12.76 | — |
| Shares, diluted (wtd. avg.) | 47.7M | 33.2M | 31.2M | 30.9M | 15.0M | 1.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.9M | $4.0M | $3.9M | $29.9M | $58.9M | $13.5M | $21.4M |
| Short-term investments | $35.3M | $42.2M | $45.2M | $52.8M | $46.2M | $0 | — |
| Receivables | $12.0K | $34.0K | $160.0K | $113.0K | $27.0K | $2.0K | — |
| Total current assets | $40.8M | $47.6M | $61.3M | $90.1M | $110.3M | $13.7M | — |
| Property, plant and equipment | — | — | — | — | $1.8M | $965.0K | — |
| Other intangibles | $910.0K | $1.0M | $0 | — | — | — | — |
| Total assets | $101.9M | $72.6M | $95.4M | $116.3M | $147.0M | $14.8M | — |
| Accounts payable | $862.0K | $2.0M | $1.0M | $1.5M | $1.2M | $441.0K | — |
| Total current liabilities | $24.2M | $24.8M | $24.4M | $15.5M | $8.4M | $11.2M | — |
| Total liabilities | $26.5M | $24.8M | $25.3M | $17.4M | $8.5M | $12.3M | — |
| Retained earnings | -$311.7M | -$279.8M | -$246.9M | -$210.7M | -$166.5M | -$131.5M | — |
| Total equity | $75.4M | $47.8M | $70.2M | $98.9M | $138.6M | -$125.6M | -$106.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.6M | -$14.2M | -$27.2M | -$34.6M | -$31.6M | -$16.9M | — |
| Depreciation and amortisation | $940.0K | $833.0K | $900.0K | $756.0K | $659.0K | $895.0K | — |
| Stock-based compensation | $5.1M | $7.0M | $5.3M | $5.1M | $3.1M | $726.0K | — |
| Capital expenditure | $726.0K | $56.0K | $128.0K | $791.0K | $1.3M | $149.0K | — |
| Investing cash flow | -$28.5M | $11.7M | $438.0K | $5.6M | -$82.6M | -$149.0K | — |
| Financing cash flow | $54.0M | $2.6M | $752.0K | $5.0K | $159.6M | $9.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001534969-26-000009.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $25.0K | $82.0K | $268.0K | $306.0K | $77.0K | $81.0K |
| Gross profit | — | — | — | — | $96.0K | -$5.0K | -$83.0K |
| Net income | — | -$19.8M | -$35.0M | -$44.2M | -$36.2M | -$32.9M | -$31.9M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Item 5.02
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $58.23B | — | 35.9% |
| DGX | QUEST DIAGNOSTICS INC | $26.70B | 27.6x | 11.8% |
| LH | LABCORP HOLDINGS INC. | $26.68B | 31.4x | 7.2% |
| GH | Guardant Health, Inc. | $22.69B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $9.04B | — | 97.0% |
| GRAL | GRAIL, Inc. | $5.92B | — | 17.2% |
| RDNT | RadNet, Inc. | $5.54B | — | 11.5% |
| BLLN | BillionToOne, Inc. | $5.00B | 769.8x | 100.0% |